Today, on 30 July, the Vice Minister of Health of the People’s Republic of China Zhang Mao and delegation with high officials lead by him are visiting joint stock company Grindeks.
The Vice Minister of Health of the People’s Republic of China Zhang Mao and delegation representatives met with the Chairman of the Council Kirovs Lipmans, the Chairman of the Board Juris Bundulis and other management representatives of JSC Grindeks. During the meeting the officials discussed medication registration and clinical researches in the People’s Republic of China, as well as visited the manufacturing units of Grindeks.
Chairman of the Council of JSC Grindeks Kirovs Lipmans: “Last year the Mildronate® pharmacokinetic study was successfully completed and currently the preparation work is being done for the start of the clinical research in the People’s Republic of China. Today, the discussions were encouraging and in a mutually interested sense, leading to a belief that we will overcome all obstacles and will launch our business in the People’s Republic of China successfully.”
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.
Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.
Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.
During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.
JSC Grindeks shares are listed in the Official List of „Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans –33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” (nominal holder) – 10.53%, “Swedbank” AS Clients Account (nominal holder) – 8.79%.
More information about the company – www.grindeks.lv/en/
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: [email protected]